Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Thousand Oaks, California, California United States of America
Amgen discontinues development of AMG-786 and focuses on MariTide for obesity treatment
Amgen plans late-stage studies for MariTide in obesity, obesity-related conditions, and diabetes
Amgen's shares rise significantly following the announcement
MariTide is an injectable drug in Phase 2 trials that showed promising results with patients losing an average of 14.5% body weight in 12 weeks
MariTide will likely be delivered in a handheld autoinjector used monthly
Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Amgen, a biotech company based in Thousand Oaks, California, has announced that it will no longer develop its early-stage obesity pill and instead focus on the injectable drug MariTide. The decision comes after encouraging interim results from a Phase 2 trial of MariTide were reported. Amgen CEO Robert Bradway expressed confidence in the drug's potential to address important unmet medical needs in obesity, diabetes, and obesity-related conditions.

According to reports, MariTide is an injectable drug for obesity that is currently in a Phase 2 trial. The interim analysis of this trial has shown promising results, leading Amgen to discontinue development of its oral drug AMG-786 and focus solely on MariTide.

The exact details of the interim analysis have not been released, but it is known that patients given the highest dose of MariTide lost an average of 14.5% of their body weight in just 12 weeks according to phase one trial data published in Nature Metabolism.

Amgen's decision to focus on MariTide comes as the market for obesity treatments continues to grow rapidly. Novo Nordisk and Eli Lilly are currently dominating the space with their weight-loss drugs Wegovy and Zepbound, respectively. However, Amgen believes that MariTide's differentiated profile will allow it to capture a significant share of this market.

Amgen is planning late-stage studies for MariTide in obesity, obesity-related conditions, and diabetes. The drug will likely be delivered in a handheld autoinjector that is used monthly. Amgen has already initiated activities to expand manufacturing capacity for MariTide with both clinical and commercial supply in mind.

The news of Amgen's focus on MariTide has been well received by the market, with the company's shares rising significantly in after-hours trading following the announcement.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

85%

Doubts
  • It's unknown how MariTide compares to other obesity drugs currently on the market, such as Wegovy and Zepbound
  • The exact details of the interim analysis have not been released, so it's unclear if these results are statistically significant or representative

Sources

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work

Endpoints News Drew Armstrong Friday, 03 May 2024 04:03
  • Unique Points
    • Amgen announced positive results from a Phase 2 trial of its anti-obesity drug MariTide, calling the company ‘very encouraged.’
    • The company plans to rapidly move forward with a final-stage program as well as boost manufacturing capacity for the experimental drug.
    • Amgen CEO Bob Bradway expressed confidence in MariTide’s differentiated profile and believes it will address important unmet medical need.
  • Accuracy
    • Amgen plans to rapidly move forward with a final-stage program as well as boost manufacturing capacity for the experimental drug.
    • Amgen has discontinued development of its experimental weight loss pill.
    • MariTide is in an ongoing midstage trial and initial data will be released later this year.
    • Amgen plans a late-stage trial for MariTide in obesity and a stage two trial in diabetes treatment.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Amgen scraps experimental weight loss pill, moves forward with injection

CNBC News Annika Kim Thursday, 02 May 2024 21:00
  • Unique Points
    • Amgen has discontinued development of its experimental weight loss pill.
    • , Amgen is moving forward with an injectable drug called MariTide for obesity treatment.
    • , MariTide appears to help patients keep weight off after they stop taking it based on some clinical trial data.
    • , Patients given the highest dose of MariTide lost 14.5% of their body weight on average in just 12 weeks according to phase one trial data published in Nature Metabolism.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article contains some instances of appeals to authority and inflammatory rhetoric, but no formal or blatant logical fallacies were found. The author quotes Amgen's chief scientific officer, Jay Bradner, and mentions Wall Street analysts' expectations as sources of information. The author also uses descriptive language to convey the significance of Amgen's decision to stop developing its oral weight loss pill and focus on its injectable drug instead.
    • ]Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly,
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Amgen Soars After CEO Gives Update on Experimental Obesity Drug

Yahoo Finance Madison Muller Friday, 03 May 2024 04:05
  • Unique Points
    • Amgen's shares soared in late trading after its CEO said he was 'very encouraged'' with the interim results of its obesity treatment, MariTide.
    • Amgen has announced that it will no longer develop its early-stage obesity pill and instead focus on the injectable drug MariTide.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Amgen goes all in on injectable obesity drug as it scraps early-stage pill

STAT News Elaine Chen Thursday, 02 May 2024 22:45
  • Unique Points
    • Amgen has announced that it will no longer develop its early-stage obesity pill and instead focus on the injectable drug MariTide.
    • MariTide is a Phase 2 trial injectable drug for obesity, with topline data expected late this year.
    • Amgen’s CEO, Bob Bradway, expressed encouragement from interim analysis results of the MariTide trial.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Amgen Is 'Very Encouraged' With Its Obesity Study; Shares Rocket 13%

Investors.com Financial News Site Analysis - Comprehensive Report on Market Coverage and Analysis - Overall Rating: 90/100 (Highly Reliable, Informative, and Engaging Source of Financial Information). Investor's Business Thursday, 02 May 2024 22:55
  • Unique Points
    • Amgen is ‘very encouraged’ with the interim results of its obesity treatment, MariTide.
    • Amgen plans Phase 3 studies for MariTide and has completed a Phase 1 study for another obesity drug, AMG 786.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article contains some instances of appeals to authority when it mentions the success or struggles of specific drugs from Eli Lilly and Novo Nordisk. However, no formal fallacies were found in the text provided.
    • ] Amgen is on track to potentially rival blockbuster weight-loss drugs from Eli Lilly and Novo Nordisk.[
    • Both are struggling with their own success, however.[
    • If successful, Amgen would rival Novo’s Wegovy and Lilly’s Zepbound.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication